| Autor: |
Brodsky B; Department of Biomedical Engineering, Tufts University, Medford, MA, USA. barbara.brodsky@tufts.edu., Ramshaw JA; CSIRO Manufacturing, Bayview Avenue, Clayton, VIC, 3169, Australia. |
| Jazyk: |
angličtina |
| Zdroj: |
Sub-cellular biochemistry [Subcell Biochem] 2017; Vol. 82, pp. 601-629. |
| DOI: |
10.1007/978-3-319-49674-0_18 |
| Abstrakt: |
There is a great deal of interest in obtaining recombinant collagen as an alternative source of material for biomedical applications and as an approach for obtaining basic structural and biological information. However, application of recombinant technology to collagen presents challenges, most notably the need for post-translational hydroxylation of prolines for triple-helix stability. Full length recombinant human collagens have been successfully expressed in cell lines, yeast, and several plant systems, while collagen fragments have been expressed in E. coli. In addition, bacterial collagen-like proteins can be expressed in high yields in E. coli and easily manipulated to incorporate biologically active sequences from human collagens. These expression systems allow manipulation of biologically active sequences within collagen, which has furthered our understanding of the relationships between collagen sequences, structure and function. Here, recombinant studies on collagen interactions with cell receptors, extracellular matrix proteins, and matrix metalloproteinases are reviewed, and discussed in terms of their potential biomaterial and biomedical applications. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
